[go: up one dir, main page]

PE20011082A1 - UNA NUEVA FORMA CRISTALINA DEL ACIDO N-[4-[2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d] PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO Y PROCEDIMIENTO PARA SU PREPARACION - Google Patents

UNA NUEVA FORMA CRISTALINA DEL ACIDO N-[4-[2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d] PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO Y PROCEDIMIENTO PARA SU PREPARACION

Info

Publication number
PE20011082A1
PE20011082A1 PE2001000194A PE2001000194A PE20011082A1 PE 20011082 A1 PE20011082 A1 PE 20011082A1 PE 2001000194 A PE2001000194 A PE 2001000194A PE 2001000194 A PE2001000194 A PE 2001000194A PE 20011082 A1 PE20011082 A1 PE 20011082A1
Authority
PE
Peru
Prior art keywords
glutamic
oxo
ethyl
amino
pyrimidin
Prior art date
Application number
PE2001000194A
Other languages
English (en)
Inventor
Erik Christopher Chelius
Den Berghe Snorek Sharon Van
Susan Marie Reutzel-Edens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20011082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20011082A1 publication Critical patent/PE20011082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A LA FORMA CRISTALINA HIDRATO DE LA SAL DISODICA DEL ACIDO N-[4-(2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d]PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO (FORMA CRISTALINA HEPTAHIDRATO) QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X CARACTERISTICO QUE COMPRENDE LOS SIGUIENTES PICOS CORRESPONDIENTES A DISTANCIAS INTERPLANARES d: 7,78 +/- 0,04 A° CUANDO SE OBTIENE A 22 +/- 2°C Y CON UN PORCENTAJE DE HUMEDAD RELATIVA AMBIENTAL A PARTIR DE UNA FUENTE DE RADIACION DE COBRE. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION QUE COMPRENDE LA CRISTALIZACION DE LA SAL DISODICA DEL N-[4-(2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d]PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO DE UNA SOLUCION QUE COMPRENDE LA SAL DISODICA EN AGUA Y UN SOLVENTE MISCIBLE EN AGUA Y CALENTAR LA SOLUCION CON NITROGENO HUMEDECIDO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DEL CANCER
PE2001000194A 2000-02-25 2001-02-23 UNA NUEVA FORMA CRISTALINA DEL ACIDO N-[4-[2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d] PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO Y PROCEDIMIENTO PARA SU PREPARACION PE20011082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25

Publications (1)

Publication Number Publication Date
PE20011082A1 true PE20011082A1 (es) 2001-10-22

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000194A PE20011082A1 (es) 2000-02-25 2001-02-23 UNA NUEVA FORMA CRISTALINA DEL ACIDO N-[4-[2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d] PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO Y PROCEDIMIENTO PARA SU PREPARACION

Country Status (35)

Country Link
US (1) US7138521B2 (es)
EP (1) EP1259513B1 (es)
JP (1) JP4846158B2 (es)
KR (1) KR100744917B1 (es)
CN (1) CN1183135C (es)
AR (1) AR029471A1 (es)
AT (1) ATE249462T1 (es)
AU (1) AU777047B2 (es)
BR (1) BR0108604A (es)
CA (1) CA2400155C (es)
CO (1) CO5261585A1 (es)
CZ (1) CZ303772B6 (es)
DE (1) DE60100750T2 (es)
DK (1) DK1259513T3 (es)
DZ (1) DZ3283A1 (es)
EA (1) EA004684B1 (es)
EG (1) EG24073A (es)
ES (1) ES2206403T3 (es)
HR (1) HRP20020701B1 (es)
HU (1) HU229704B1 (es)
IL (2) IL150480A0 (es)
MX (1) MXPA02008242A (es)
MY (1) MY124784A (es)
NO (1) NO323422B1 (es)
NZ (1) NZ519796A (es)
PE (1) PE20011082A1 (es)
PL (1) PL208061B1 (es)
PT (1) PT1259513E (es)
SI (1) SI1259513T1 (es)
SK (1) SK287375B6 (es)
SV (1) SV2002000321A (es)
TW (1) TWI237024B (es)
UA (1) UA72791C2 (es)
WO (1) WO2001062760A2 (es)
ZA (1) ZA200205265B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
EP1954284A4 (en) * 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA AND PEMETREXED
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
US8629152B2 (en) * 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
EP1934226A2 (en) * 2006-08-14 2008-06-25 Sicor, Inc. Highly pure pemetrexed diacid and processes for the preparation thereof
KR101101443B1 (ko) 2006-08-14 2012-01-03 시코르, 인크. 페메트렉세드의 중간체의 제조 방법
ATE490257T1 (de) * 2006-08-14 2010-12-15 Sicor Inc Kristalline formen von pemetrexed-disäure und herstellungsverfahren dafür
US20100113392A1 (en) * 2006-11-03 2010-05-06 Badros Ashraf Z Methods of using saha and bortezomib for treating multiple myeloma
BRPI0807939A2 (pt) * 2007-04-03 2014-07-01 Reddys Lab Ltd Dr Formas sólidas de pemetrexed
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
EP2072518A1 (en) 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
WO2010028105A2 (en) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Amorphous pemetrexed disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
ES2639639T3 (es) 2011-03-25 2017-10-27 Scinopharm Taiwan, Ltd. Proceso para la producción de pemetrexed disódico
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
WO2014122460A2 (en) 2013-02-06 2014-08-14 Cipla House Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
EP3308770A1 (en) 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
EP3008064B1 (en) 2013-06-14 2017-11-22 Synthon B.V. Stable pemetrexed arginine salt and compositions comprising it
US9688682B2 (en) 2013-07-16 2017-06-27 Dr. Reddy's Laboratories Limited Crystalline forms of pemetrexed tromethamine salts
WO2015050230A1 (ja) 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
WO2016068796A1 (en) 2014-10-30 2016-05-06 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
CN109906071A (zh) * 2017-10-10 2019-06-18 太阳制药工业公司 培美曲塞的静脉输注剂型
JP7490239B2 (ja) 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化ペメトレキセドおよびその使用
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
EP0923287A4 (en) * 1996-08-30 2001-08-01 Lilly Co Eli NON-CLASSIC PYRROLO (2,3-D) PYRIMIDINE ANTIFOLATE
AU740087B2 (en) * 1997-09-26 2001-11-01 Eli Lilly And Company Processes and intermediates useful to make antifolates
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
EP1212325A2 (en) * 1999-08-23 2002-06-12 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
CN1183135C (zh) 2005-01-05
WO2001062760A2 (en) 2001-08-30
NO20023974L (no) 2002-08-21
CN1406238A (zh) 2003-03-26
ES2206403T3 (es) 2004-05-16
DK1259513T3 (da) 2004-01-12
HRP20020701A2 (en) 2003-12-31
ATE249462T1 (de) 2003-09-15
DE60100750D1 (de) 2003-10-16
WO2001062760A3 (en) 2001-12-06
SK11862002A3 (sk) 2003-01-09
PL356423A1 (en) 2004-06-28
AU3445101A (en) 2001-09-03
KR100744917B1 (ko) 2007-08-01
HUP0204232A2 (hu) 2003-04-28
CO5261585A1 (es) 2003-03-31
IL150480A (en) 2007-12-03
BR0108604A (pt) 2002-11-19
HUP0204232A3 (en) 2006-01-30
AU777047B2 (en) 2004-09-30
EP1259513A2 (en) 2002-11-27
HRP20020701B1 (en) 2011-02-28
MXPA02008242A (es) 2002-11-29
EA200200905A1 (ru) 2003-02-27
TWI237024B (en) 2005-08-01
DZ3283A1 (fr) 2001-08-30
JP4846158B2 (ja) 2011-12-28
NO323422B1 (no) 2007-04-30
CZ303772B6 (cs) 2013-05-02
DE60100750T2 (de) 2004-07-29
HU229704B1 (en) 2014-05-28
EA004684B1 (ru) 2004-06-24
US7138521B2 (en) 2006-11-21
PT1259513E (pt) 2004-02-27
AR029471A1 (es) 2003-07-02
US20030216416A1 (en) 2003-11-20
MY124784A (en) 2006-07-31
HK1051856A1 (en) 2003-08-22
CA2400155C (en) 2009-09-15
KR20020075449A (ko) 2002-10-04
SK287375B6 (sk) 2010-08-09
ZA200205265B (en) 2003-11-11
SI1259513T1 (en) 2003-12-31
EG24073A (en) 2008-05-11
UA72791C2 (uk) 2005-04-15
EP1259513B1 (en) 2003-09-10
SV2002000321A (es) 2002-07-16
NO20023974D0 (no) 2002-08-21
CZ20022875A3 (cs) 2003-02-12
IL150480A0 (en) 2002-12-01
CA2400155A1 (en) 2001-08-30
JP2003530321A (ja) 2003-10-14
PL208061B1 (pl) 2011-03-31
NZ519796A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
PE20011082A1 (es) UNA NUEVA FORMA CRISTALINA DEL ACIDO N-[4-[2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d] PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO Y PROCEDIMIENTO PARA SU PREPARACION
CO5200767A1 (es) Nueva forma cristalina de la sal disodica del acido n-[4-[2-(2- amino 4,7-dihidro-4-oxo-3h-pirrolo [2,3-d]- pirimidin-5-il] etil] benzoil]-l- glutamico y procedimiento para el mismo
BR0207400A (pt) Fusão controlada em uma configuração invertida de campo e conversão de energia direta
WO2001096336A3 (en) 6,5-fused bicyclic heterocycles
BR0112857A (pt) Compostos 2-(4-piridil)amino-6-dialcoxifenil-pirido-[2,3-d]pirimidin- 7-onas
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
BR0016164A (pt) Composto,composição farmacêutica, uso de um composto, e, métodos para o tratamento e/ou profilaxia de asma, alergia, artrite, incluindo artrite reumatóide e espondiloartrite, gota, ateroesclerose, doença intestinal inflamatória crÈnica (doença de crohn), distúrbios dermatológicos inflamatórios e proliferativos, psorìase, dermatite atópica, uveìte, choque séptico, aids e osteoporose e para o tratamento de acne
CO5670355A2 (es) Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico
EA200800067A1 (ru) Нестероидные антиандрогены, направленные на 12 спираль (рецептора андрогенов)
SE0100822D0 (sv) Method II to obtain microparticles
RU98102777A (ru) Соли производных амидина и ингибитора циклооксигеназы, способ их получения, их применение в качестве медикаментов и фармацевтические композиции на их основе
NO20035694D0 (no) Nye sulfonsyrederivater
CO5251405A1 (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida
BR0109542A (pt) Derivados de imidazopirina alquilados
ATE425963T1 (de) Sulfonsauresalze von mandelsaurederivaten
SV2002000132A (es) Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi) -2-(4-metoxifenil)benzo[b]tiofeno ref. x-11357.
AR027624A1 (es) Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos
CO5160316A1 (es) N-oxidos de las correspondientes bases libres inhibidoras de la fosfodiesterasa iv y su uso para el tratamiento de enfer- medades inflamatorias
ECSP045232A (es) Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral
CO5170530A1 (es) Procedimietno para preparar derivados de 10,11-metanobenzosuberano
PL373247A1 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
DK1140810T3 (da) Benzensulfonamidderivater samt deres anvendelse
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
NO20081264L (no) Krystallinske former av {(1R),2S]-2-Aminopropionsyre 2-[4-(4-Fluor-2-Metyl-1H-Indol-5-Yloksy)-5-Metylpyrrolo[2,1-F][1,2,4]Triazin-6-Yloksy]-1-Metyletylester
CO5630027A2 (es) Agentes terapeuticos derivados de acido 3-fenilpropionico sustituido

Legal Events

Date Code Title Description
FC Refusal